2025-06-09-花旗集团-艾维迪蒂生物科学公司（RNA）_Avidity_Biosciences公司（RNA.O）_与FDA达成一致_生物制品许可申请（BLA）路径明确_管理层会议要点_12页_458kb

Avidity Biosciences Inc (RNA.O) Summary

Core Content

Avidity Biosciences Inc (RNA.O) is a research-based biotechnology company focused on the development of AOCs (Antisense Oligonucleotide Therapies) for the treatment of neuromuscular conditions. The company is currently evaluating del-brax for the treatment of Facioscapulohumeral Muscular Dystrophy (FSHD) and has received positive regulatory alignment with the FDA for using cDUX as a biomarker. This alignment, along with topline clinical data showing a clinically meaningful response, supports the potential for a Biologics License Application (BLA) filing in the second half of 2026 (2H26).

The company plans to utilize a Q6W (every six weeks) dosing regimen of 2mg/kg in both the biomarker cohort and the phase 3 FORWARD trial. The 12-month functional data showed preserved mobility and strength, as well as improvements in quality of life measures, which are significant for FSHD patients. Early data from the FORTITUDE-OLE study also suggests encouraging disease control.

Avidity is expected to file a BLA for del-brax in 2H26, which is one of three BLA filings anticipated over the next 18 months. This indicates a strong pipeline and potential for multiple AOC product launches in the rare disease space. The company's management has highlighted the ease of testing and the direct relationship of the chosen biomarker to the underlying disease pathology, reinforcing the clinical relevance of del-brax.

Key Information

• Target Price: $75 (up from $70)
• Current Price: $36.24
• Expected Share Price Return: 107.0%
• Market Cap: $4,368M
• Investment Rating: Buy/High Risk
• BLA Filing: Expected in 2H26 for del-brax
• Launch Timeline: Del-brax is expected to launch in the US in 2027, with additional geographies in 2028
• Sales Revenue Projections:
  • 2025E: $13M
  • 2026E: $34M
  • 2027E: $507M
• Risk Factors:
  • High risk due to the usual volatility of biotech stocks
  • Uncertainty in clinical trials, late-stage drug development, and regulatory decisions
  • Potential for commercial competition
  • Clinical trial failures
  • High development costs and potential need for equity or product financing

Main Points

• Positive Regulatory Alignment: The FDA has aligned with the use of cDUX as a biomarker for del-brax, which is crucial for the accelerated approval pathway.
• Clinical Data: 12-month functional data showed clinically meaningful outcomes, including preserved mobility and strength, as well as improvements in quality of life.
• BLA Filing: A BLA filing for del-brax is anticipated in 2H26, with potential for multiple BLA filings over the next 18 months.
• Investment Outlook: The company is well-positioned for commercial success with its AOC platform and pipeline products, leading to an increased PoS (Probability of Success) for del-brax to 80% from 70%.
• Valuation: The target price of $75 is based on a DCF model with a WACC of 12.5% and a 2% terminal growth rate.
• Financial Metrics:
  • EBIT (Adj) for 2027E is projected at -$140M, with an EBIT Margin of -27.6%
  • Pre-tax profit for 2027E is -$138M
  • Free cash flow to shareholders for 2027E is -$49M
• Company Description: Avidity is a biotechnology company with a focus on AOCs for neuromuscular diseases, and plans to file its first BLA in 4Q25.

Analyst Takeaways

• The management meeting indicated strong confidence in the regulatory and clinical progress of del-brax.
• The company is expected to have a significant impact on the market with the launch of multiple AOC products.
• The increased target price and PoS reflect the positive outlook on the company's future performance and potential for commercial success.
• The investment rating of Buy/High Risk acknowledges the high risk associated with the biotech sector but also highlights the potential for substantial returns.